Parkinson’s-Fighting Biotech Snags $75M In Series A Funding

Law360 (March 8, 2018, 6:26 PM EST) -- Prevail Therapeutics Inc., a New York biotechnology company focused on fighting neurodegenerative diseases like Parkinson’s, on Thursday said it pocketed $75 million in its latest funding round thanks to investors including private equity and venture capital firm OrbiMed Advisors.

Along with OrbiMed, investors in the Series A round include Alexandria Real Estate Equities Inc.’s strategic venture capital arm, hedge fund sponsors Adage Capital Management LP and EcoR1 Capital, and investment firms Boxer Capital, BVF Partners LP, RA Capital Management LLC and Omega Funds.

Prevail’s CEO and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.